Purinergic Signaling in Pancreas - From Physiology to Therapeutic Strategies in Pancreatic Cancer
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Purinergic Signaling in Pancreas - From Physiology to Therapeutic Strategies in Pancreatic Cancer. / Novak, Ivana; Yu, Haoran; Magni, Lara; Deshar, Ganga.
I: International Journal of Molecular Sciences (Online), Bind 21, Nr. 22, 8781, 2020.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Purinergic Signaling in Pancreas - From Physiology to Therapeutic Strategies in Pancreatic Cancer
AU - Novak, Ivana
AU - Yu, Haoran
AU - Magni, Lara
AU - Deshar, Ganga
PY - 2020
Y1 - 2020
N2 - The purinergic signaling has an important role in regulating pancreatic exocrine secretion. The exocrine pancreas is also a site of one of the most serious cancer forms, the pancreatic ductal adenocarcinoma (PDAC). Here, we explore how the network of purinergic and adenosine receptors, as well as ecto-nucleotidases regulate normal pancreatic cells and various cells within the pancreatic tumor microenvironment. In particular, we focus on the P2X7 receptor, P2Y2 and P2Y12 receptors, as well as A2 receptors and ecto-nucleotidases CD39 and CD73. Recent studies indicate that targeting one or more of these candidates could present new therapeutic approaches to treat pancreatic cancer. In pancreatic cancer, as much as possible of normal pancreatic function should be preserved, and therefore physiology of purinergic signaling in pancreas needs to be considered.
AB - The purinergic signaling has an important role in regulating pancreatic exocrine secretion. The exocrine pancreas is also a site of one of the most serious cancer forms, the pancreatic ductal adenocarcinoma (PDAC). Here, we explore how the network of purinergic and adenosine receptors, as well as ecto-nucleotidases regulate normal pancreatic cells and various cells within the pancreatic tumor microenvironment. In particular, we focus on the P2X7 receptor, P2Y2 and P2Y12 receptors, as well as A2 receptors and ecto-nucleotidases CD39 and CD73. Recent studies indicate that targeting one or more of these candidates could present new therapeutic approaches to treat pancreatic cancer. In pancreatic cancer, as much as possible of normal pancreatic function should be preserved, and therefore physiology of purinergic signaling in pancreas needs to be considered.
KW - Fibrosis
KW - Immune cells
KW - Immunotherapy
KW - Inflammation
KW - Ion channels
KW - Pancreatic cancer
KW - Pancreatic stellate cells
KW - Pancreatitis
KW - PDAC
KW - PSC
U2 - 10.3390/ijms21228781
DO - 10.3390/ijms21228781
M3 - Review
C2 - 33233631
AN - SCOPUS:85096316937
VL - 21
JO - International Journal of Molecular Sciences (Online)
JF - International Journal of Molecular Sciences (Online)
SN - 1661-6596
IS - 22
M1 - 8781
ER -
ID: 253023960